Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127218 · ClinicalTrials.gov registry record · Phase 3
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
A Phase 3 study of Cardiovascular Disease and Atherosclerosis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT00127218 is a Phase 3 study of Cardiovascular Disease and Atherosclerosis that has completed, run by Johns Hopkins University. The registered enrollment target is 145 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00127218, a Phase 3 study of Cardiovascular Disease and Atherosclerosis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older individuals with cardiovascular disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG niacin
- DRUG any statin
Study Locations (1)
Maryland
- Johns Hopkins Unversity School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127218
The ClinicalTrials.gov registry entry for NCT00127218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (95% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00127218 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00127218 about?
NCT00127218 is a clinical study titled "High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly". The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older individuals with cardiovascular disease.
What is the current status of trial NCT00127218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2003-09. Estimated completion is 2008-12.
What conditions does trial NCT00127218 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Atherosclerosis.
What interventions are being tested in trial NCT00127218?
The interventions under investigation include: Placebo (DRUG), niacin (DRUG), any statin (DRUG).
Who is sponsoring clinical trial NCT00127218?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00127218 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.